Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 244 | 106 | 208 | 1,128 | 437 |
| Receivables | 200 | 452 | N/A | 100 | 200 |
| Other current assets | 0 | 0 | 0 | 245 | 251 |
| TOTAL | $745 | $958 | $534 | $1,473 | $888 |
| Non-Current Assets | |||||
| PPE Net | 83 | 87 | 85 | 63 | 69 |
| Intangibles | 1,403 | 1,570 | 1,738 | 1,906 | 2,074 |
| Other Non-Current Assets | 827 | 821 | 1,495 | 1,488 | 1,480 |
| TOTAL | $2,313 | $2,478 | $3,319 | $3,456 | $3,623 |
| Total Assets | $3,058 | $3,436 | $3,852 | $4,929 | $4,510 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,682 | 3,271 | 3,552 | 3,274 | 2,771 |
| TOTAL | $4,642 | $3,598 | $4,061 | $3,594 | $2,931 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 10,912 | 9,858 | 7,100 | 5,550 | 2,500 |
| TOTAL | $10,912 | $9,858 | $7,100 | $5,550 | $2,500 |
| Total Liabilities | $15,554 | $13,455 | $11,161 | $9,144 | $5,431 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 380,691 | 378,888 | 370,737 | 370,365 | 370,355 |
| Common Shares | 379 | 371 | 371 | 370 | 370 |
| Retained earnings | -221,641 | -218,741 | -216,019 | -212,908 | -209,613 |
| TOTAL | $-12,496 | $-10,019 | $-7,309 | $-4,215 | $-920 |
| Total Liabilities And Equity | $3,058 | $3,436 | $3,852 | $4,929 | $4,510 |